Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claim 1. (Currently Amended) A compound of the formula



I

wherein X_1 is O, $S(O)_n$, $-\overset{R^5}{N}-$, $-CO-\overset{R^6}{N}-$, or $-CH_2-$, with the proviso that when X_1 is $-CH_2-$, R^1 and R^2 are only halogen;

n is 0, 1 or 2;

R^a and R^b when taken together form an oxo (=O) group, or R^a and R^b are each independently hydrogen, OH, $OCOR^9$, NH_2, N_3, $NHCOOR^9$, $NHCOCOR^9$, $NHSO_2R^9$ or F;

X is H, CF_3, OCF_3, halogen, C_1–C_7 alkyl, C_2–C_7 alkenyl, C_2–C_7 alkynyl or C_3–C_7 cycloalkyl, said alkyl, alkenyl, alkynyl or cycloalkyl group being optionally substituted by $COOR^8$, CN, $C(O)NR^6R^7$, PO_3R^8, SO_3R^8, ~~heterocyclic,~~ OR^8, SH, $S(O)_nR^9$, NR^6R^7, $NH(CO)NR^6R^7$, $NH(CO)OR^9$, or aryl ~~or heteroaryl~~, said aryl ~~or heteroaryl~~ being optionally substituted by one or two groups independently selected from NR^6R^7, OR^8, $COOR^8$, SO_3R^8, $OCOR^9$, PO_3R^8, and $C(O)NR^6R^7$ ~~and heterocyclic~~;

R^1 and R^2 are each independently H, halogen, OR^9, C_1–C_7 alkyl, C_2–C_7 alkynyl,

C_2–C_7 alkenyl or C_3–C_7 cycloalkyl, said alkyl, alkenyl, alkynyl and cycloalkyl group being optionally substituted by $COOR^8$, CN, $C(O)NR^6R^7$, PO_3R^8, SO_3R^8, ~~heterocyclic~~, OR^8, SH, $S(O)_nR^9$, NR^6R^7, $NH(CO)NR^6R^7$, $NH(CO)OR^9$, $OC(O)OR^9$, or aryl ~~or heteroaryl~~, said aryl ~~and heteroaryl~~ being optionally substituted with one or two groups independently selected from NR^6R^7, OR^8, $COOR^8$, SO_3R^8, $OCOR^9$, PO_3R^8, and $C(O)NR^6R^7$ ~~and heterocyclic~~;

R^3, R^4 and Y are each independently H, halogen, OR^{10}, $S(O)_nR^{10}$, C_1–C_7 alkyl, C_2–C_7 alkenyl, C_2–C_7 alkynyl or C_3–C_7 cycloalkyl, said alkyl, alkenyl, alkynyl and cycloalkyl group being optionally substituted by $COOR^8$, CN, $C(O)NR^6R^7$, PO_3R^8, SO_3R^8, ~~heterocyclic,~~ OR^8, SH, $S(O)_nR^9$, NR^6R^7, $NH(CO)NR^6R^7$, $NH(CO)OR^9$, $OC(O)OR^9$, or aryl ~~or heteroaryl~~, said aryl ~~and heteroaryl~~ being optionally substituted by one or two groups independently selected from NR^6R^7, OR^8, $COOR^8$, SO_3R^8, $OCOR^8$, PO_3R^8, and $C(O)NR^6R^7$ ~~and heterocyclic~~, with the proviso that not all of R^3, R^4 and Y may be the same halogen;

R^5, R^6 and R^7 are each independently H, C_1–C_7 alkyl, C_2–C_7 alkenyl, C_2-C_7 alkynyl or C_3–C_7 cycloalkyl, said alkyl, alkenyl, alkynyl and cycloalkyl group being optionally substituted by $COOR^8$, CN, OR^8, NR^8R^9, SO_3R^8, PO_3R^8, halogen, or aryl ~~or heteroaryl~~, said aryl ~~or heteroaryl~~ being optionally substituted by one or two groups independently selected from $COOR^8$, SO_3R^8, and PO_3R^8 ~~and heterocyclic~~;

R^8 is H, C_1–C_7 saturated straight chain alkyl or cycloalkyl;

R^9 is C_1–C_7 saturated straight chain alkyl or cycloalkyl;

R^{10} is C_1–C_7 alkyl, C_2–C_7 alkenyl, C_2–C_7 alkynyl, aryl or C_3–C_7 cycloalkyl, said alkyl, alkenyl, alkynyl, aryl or cycloalkyl group being optionally substituted by

$COOR^8$, CN, $C(O)NR^6R^7$, PO_3R^8, SO_3R^8, ~~heterocyclic~~, OR^8, SH, $S(O)_nR^9$, NR^6R^7, $NH(CO)NR^6R^7$, $NH(CO)OR^9$, or aryl ~~or heteroaryl~~, said aryl ~~or heteroaryl~~ being optionally substituted by one or two groups independently selected from NR^6R^7, OR^8, $COOR^8$, SO_3R^8, $OCOR^8$, PO_3R^8, and $C(O)NR^6R^7$ ~~and heterocyclic~~;

Z is OR^{11}, $S(O)_nR^{11}$, $NR^{11}R^{12}$ or $CHR^{11}R^{12}$;

R^{11} is C_1–C_7 alkyl, C_2–C_7 alkenyl, C_2–C_7 alkynyl or C_3–C_7 cycloalkyl, said alkyl, alkenyl, alkynyl or cycloalkyl group being substituted by $NR^{13}R^{14}$, $S(O)_nR^{13}$, or OR^{13};

R^{12} is hydrogen, C_1–C_7 alkyl, C_2–C_7 alkenyl, C_2–C_7 alkynyl or C_3–C_7 cycloalkyl, said alkyl, alkenyl, alkynyl or cycloalkyl group being optionally substituted by $NR^{13}R^{14}$, $S(O)_nR^{13}$, or OR^{13};

R^{13} is ~~$SiR^{15}R^{16}R^{17}$~~, C_1–C_7 alkyl, C_2–C_7 alkenyl, C_2–C_7 alkynyl, aryl or C_3–C_7 cycloalkyl, said alkyl, alkenyl, alkynyl, aryl or cycloalkyl group being substituted by one to three groups independently selected from $COOR^8$, OR^8, ~~$Si R^{15}R^{16}R^{17}$~~, OR^{15}, aryl, and biaryl ~~and heteroaryl~~, said aryl[[,]] and biaryl ~~and heteroaryl~~ being optionally substituted with one to three groups independently selected from halogen, CF_3, OR^8, $COOR^8$, NO_2, and CN;

R^{14} is H, ~~$SiR^{15}R^{16}R^{17}$~~, C_1–C_7 alkyl, C_2–C_7 alkenyl, C_2–C_7 alkynyl, aryl or C_3–C_7 cycloalkyl, said alkyl, alkenyl, alkynyl, aryl or cycloalkyl group being optionally substituted by one to three groups independently selected from $COOR^8$, OR^8, ~~$Si R^{15}R^{16}R^{17}$~~, OR^{15}, aryl, and biaryl ~~and heteroaryl~~, said aryl[[,]] and biaryl ~~and heteroaryl~~ being optionally substituted with one to three groups independently selected from halogen, CF_3, OR^8, $COOR^8$, NO_2, and CN; and ~~or~~

~~R^{13} and R^{14} when taken together with the nitrogen atom to which they are attached may form a 5–7 membered heterocyclic ring with one or more heteroatoms selected from O, N and S; said ring being optionally substituted by OR^8, $COOR^8$, or $C(O)NR^5R^6$; and~~

R^{15}, ~~R^{16}, R^{17} are each independently~~ is C_1-C_7 alkyl, aryl, benzyl, benzhydryl, biaryl, ~~heteroaryl,~~ or (C_1–C_6) alkyl–aryl ~~or (C_1–C_6) alkyl–heteroaryl,~~ said aryl, benzyl, benzhydryl, and biaryl being optionally substituted by halogen, CF_3, OR^8, $COOR^8$, NO_2, CN, or C_1-C_7 alkyl.

Claim 2. (Currently Amended) A compound of the formula



I

or a pharmaceutically acceptable salt thereof wherein

X_1 is O, $S(O)_n$, $-\overset{R^5}{\underset{|}{N}}-$, $CO-\overset{R^6}{\underset{|}{N}}-$ or $-CH_2-$, with the proviso that when X_1 is $-CH_2-$, R^1 and R^2 are only halogen;

n is 0, 1 or 2;

R^a and R^b when taken together form an oxo (=O) group, or R^a and R^b are each independently hydrogen, OH, $OCOR^9$, NH_2, N_3, $NHCOOR^9$, $NHCOCOR^9$, $NHSO_2R^9$ or F;

X is H, CF_3, OCF_3, halogen, C_1–C_7 alkyl, C_2–C_7 alkenyl, C_2–C_7 alkynyl or C_3–C_7 cycloalkyl, said alkyl, alkenyl, alkynyl or cycloalkyl group being optionally substituted by $COOR^8$, CN, $C(O)NR^6R^7$, PO_3R^8, SO_3R^8, ~~heterocyclic,~~ OR^8, SH,

$S(O)_nR^9$, NR^6R^7, $NH(CO)NR^6R^7$, $NH(CO)OR^9$, or aryl ~~or heteroaryl~~, said aryl ~~or heteroaryl~~ being optionally substituted by one or two groups independently selected from NR^6R^7, OR^8, $COOR^8$, SO_3R^8, $OCOR^9$, PO_3R^8, and $C(O)NR^6R^7$ ~~and heterocyclic~~;

R^1 and R^2 are each independently H, halogen, OR^9, C_1–C_7 alkyl, C_2–C_7 alkynyl, C_2–C_7 alkenyl or C_3–C_7 cycloalkyl, said alkyl, alkenyl, alkynyl and cycloalkyl group being optionally substituted by $COOR^8$, CN, $C(O)NR^6R^7$, PO_3R^8, SO_3R^8, ~~heterocyclic,~~ OR^8, SH, $S(O)_nR^9$, NR^6R^7, $NH(CO)NR^6R^7$, $NH(CO)OR^9$, $OC(O)OR^9$, aryl ~~or heteroaryl~~, said aryl ~~and heteroaryl~~ being optionally substituted with one or two groups independently selected from NR^6R^7, OR^8, $COOR^8$, SO_3R^8, $OCOR^9$, PO_3R^8, and $C(O)NR^6R^7$ ~~and heterocyclic~~;

R^3, R^4 and Y are each independently H, OR^{10}, $S(O)_nR^{10}$, C_1–C_7 alkyl, C_2–C_7 alkenyl, C_2–C_7 alkynyl or C_3–C_7 cycloalkyl, said alkyl, alkenyl, alkynyl and cycloalkyl group being optionally substituted by $COOR^8$, CN, $C(O)NR^6R^7$, PO_3R^8, SO_3R^8, ~~heterocyclic,~~ OR^8, SH, $S(O)_nR^9$, NR^6R^7, $NH(CO)NR^6R^7$, $NH(CO)OR^9$, $OC(O)OR^9$, or aryl ~~or heteroaryl~~, said aryl ~~and heteroaryl~~ being optionally substituted by one or two groups independently selected from NR^6R^7, OR^8, $COOR^8$, SO_3R^8, $OCOR^8$, PO_3R^8, and $C(O)NR^6R^7$ ~~and heterocyclic~~;

R^5, R^6 and R^7 are each independently H, C_1–C_7 alkyl, C_2–C_7 alkenyl, C_2-C_7 alkynyl or C_3–C_7 cycloalkyl, said alkyl, alkenyl, alkynyl and cycloalkyl group being optionally substituted by $COOR^8$, CN, OR^8, NR^8R^9, SO_3R^8, PO_3R^8, halogen, or aryl ~~or heteroaryl~~, said aryl ~~and heteroaryl~~ being optionally substituted by one or two groups independently selected from $COOR^8$, SO_3R^8, and PO_3R^8 ~~and heterocyclic~~;

R^8 is H, C_1–C_7 saturated straight chain alkyl or cycloalkyl, CF_3 or CH_2CF_3;

R^9 is C_1–C_7 saturated straight chain alkyl or cycloalkyl;

R^{10} is C_1–C_7 alkyl, C_2–C_7 alkenyl, C_2–C_7 alkynyl, aryl or C_3–C_7 cycloalkyl, said alkyl, alkenyl, alkynyl, aryl or cycloalkyl group being optionally substituted by $COOR^8$, CN, $C(O)NR^6R^7$, PO_3R^8, SO_3R^8, ~~heterocyclic,~~ OR^8, SH, $S(O)_nR^9$, NR^6R^7, $NH(CO)NR^6R^7$, $NH(CO)OR^9$, or aryl ~~or heteroaryl~~, said aryl ~~or heteroaryl~~ being optionally substituted by one or two groups independently selected from NR^6R^7, OR^8, $COOR^8$, SO_3R^8, $OCOR^8$, PO_3R^8, and $C(O)NR^6R^7$ ~~and heterocyclic~~;

Z is OR^{11}, $S(O)_nR^{11}$, $NR^{11}R^{12}$ or $CHR^{11}R^{12}$;

R^{11} is C_1–C_7 alkyl, C_2–C_7 alkenyl, C_2–C_7 alkynyl or C_3–C_7 cycloalkyl, said alkyl, alkenyl, alkynyl or cycloalkyl group being substituted by $NR^{13}R^{14}$, $S(O)_nR^{13}$, or OR^{13};

R^{12} is hydrogen, C_1–C_7 alkyl, C_2–C_7 alkenyl, C_2–C_7 alkynyl or C_3–C_7 cycloalkyl, said alkyl, alkenyl, alkynyl or cycloalkyl group being optionally substituted by $NR^{13}R^{14}$, $S(O)_nR^{13}$ or OR^{13};

R^{13} is ~~$SiR^{15}R^{16}R^{17}$~~, C_1–C_7 alkyl, C_2–C_7 alkenyl, C_2–C_7 alkynyl, aryl or C_3–C_7 cycloalkyl, said alkyl, alkenyl, alkynyl, aryl or cycloalkyl group being substituted by one to three groups independently selected from $COOR^8$, OR^8, ~~$Si\text{-}R^{15}R^{16}R^{17}$~~, OR^{15}, aryl, and biaryl ~~and heteroaryl~~, said aryl[[,]] and biaryl ~~and heteroaryl~~ being optionally substituted with one to three groups independently selected from halogen, CF_3, OR^8, $COOR^8$, NO_2, and CN;

R^{14} is H, ~~$SiR^{15}R^{16}R^{17}$~~, C_1–C_7 alkyl, C_2–C_7 alkenyl, C_2–C_7 alkynyl, aryl or C_3–

C_7 cycloalkyl, said alkyl, alkenyl, alkynyl, aryl or cycloalkyl group being optionally substituted by one to three groups independently selected from $COOR^8$, OR^8, ~~$SiR^{15}R^{16}R^{17}$~~, OR^{15}, aryl, and biaryl ~~and heteroaryl~~, said aryl[[,]] and biaryl ~~and heteroaryl~~ being optionally substituted with one to three groups independently selected from halogen, CF_3, OR^8, $COOR^8$, NO_2, and CN; and ~~or~~

~~R^{13} and R^{14} when taken together with the nitrogen atom to which they are attached may form a 5 – 7 membered heterocyclic ring with one or more heteroatoms selected from O, N and S; said ring being optionally substituted by OR^8, $COOR^8$, or $C(O)NR^5R^6$; and~~

R^{15}, ~~R^{16}, R^{17} are each independently~~ is C_1-C_7 alkyl, aryl, benzyl, benzhydryl, biaryl, ~~heteroaryl,~~ or (C_1–C_6) alkyl–aryl ~~or (C_1–C_6) alkyl–heteroaryl~~, said aryl, benzyl, benzhydryl, and biaryl being optionally substituted by halogen, CF_3, OR^8, $COOR^8$, NO_2, CN, or C_1–C_7 alkyl.

Claim 3. (Currently Amended) A compound of claim 2 wherein X_1 is O or $S(O)_n$ and Y is OR^{10} in which R^{10} is C_1–C_7 alkyl, C_2–C_7 alkenyl, C_2–C_7 alkynyl, aryl or C_3–C_7 cycloalkyl, said alkyl, alkenyl, alkynyl, aryl or cycloalkyl group being optionally substituted by $COOR^8$, CN, $C(O)NR^6R^7$, PO_3R^8, SO_3R^8, ~~heterocyclic,~~ OR^8, SH, $S(O)_nR^9$, NR^6R^7, $NH(CO)NR^6R^7$, $NH(CO)OR^9$, or aryl ~~or heteroaryl~~, said aryl ~~or heteroaryl~~ being optionally substituted by one or two groups independently selected from NR^6R^7, OR^8, $COOR^8$, SO_3R^8, $OCOR^9$, PO_3R^8, and $C(O)NR^6R^7$ ~~or heterocyclic~~, said R^6, R^7, R^8 and R^9 substituents being defined as in claim 2.

Claim 4. (Original) A compound of claim 3 in which R^a and R^b taken together represent an oxo (=O) group, or R^a and R^b are each independently hydrogen or OH.

Claims 5-6. (Canceled).

Claim 7. (Currently Amended) A compound of claim 3 in which

Z is



in which m and p each independently represent an integer of one to six, ~~R^{15}, R^{16}, R^{17} are each independently C_1–C_7 alkyl or phenyl,~~ R^{18} is C_1–C_7 alkyl and aryl represents  in which X^1 is halogen.

Claim 8. (Canceled).

Claim 9. (Original) A pharmaceutical composition for the inhibition of cytosolic phospholipase A_2 comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

Claim 10. (Withdrawn) A method of inhibiting cytosolic phospholipase A_2 in a mammal in need thereof, comprising administering to said mammal a therapeutically effective amount of a compound of claim 1.

Claim 11. (Currently Amended) A compound selected from




















































,

,

;

and

or a pharmaceutically acceptable salt thereof.

Claim 12. (Currently Amended) A compound of the formula



I

or a pharmaceutically acceptable salt thereof wherein

X_1 is O, $S(O)_n$, $-CO-N(R^5)-$, or $-CH_2-$, with the proviso that when X_1 is $-CH_2-$, R^1 and R^2 are only halogen;

n is 0, 1 or 2;

R^a and R^b when taken together form an oxo (=O) group, or R^a and R^b are each independently hydrogen, OH, $OCOR^9$, NH_2, N_3, $NHCOCOR^9$, or F;

X is H;

R^1 and R^2 are each independently H, halogen, OR^9, or C_1-C_7 alkyl;

R^3, R^4 and Y are each independently H, halogen, OR^{10}, or C_1-C_7 alkyl, said alkyl being optionally substituted by aryl, said aryl being optionally substituted by one or two $COOR^8$ groups, with the proviso that not all of R^3, R^4 and Y may be the same halogen;

R^5, R^6, and R^7 are each independently hydrogen or C_1-C_7 alkyl, said alkyl being optionally substituted by OR^8;

R^8 is H or C_1-C_7 saturated straight chain alkyl;

R^9 is C_1-C_7 saturated straight chain alkyl;

R^{10} is C_1-C_7 alkyl or aryl, said alkyl or aryl group being optionally substituted by $COOR^8$, $C(O)NR^6R^7$, ~~heterocyclic,~~ or OR^8;

Z is OR^{11} or $CHR^{11}R^{12}$;

R^{11} is C_1-C_7 alkyl substituted by $NR^{13}R^{14}$, $S(O)_nR^{13}$, or OR^{13};

R^{12} is hydrogen;

R^{13} is ~~$SiR^{15}R^{16}R^{17}$ or~~ C_1-C_7 alkyl, said alkyl substituted by one to three groups independently selected from OR^{15} and aryl, said aryl substituted with one halogen;

R^{14} is C_1-C_7 alkyl; and

~~R^{15}, R^{16}, and R^{17} are each independently~~ is C_1-C_7 alkyl, aryl, or benzhydryl, said aryl and benzhydryl being optionally substituted by halogen.

Claim 13. (Currently Amended) A compound of the formula



I

or a pharmaceutically acceptable salt thereof wherein

X_1 is O, $S(O)_n$, or $-CH_2-$, with the proviso that when X_1 is $-CH_2-$, R^1 and R^2 are only halogen;

n is 0, 1 or 2;

R^a and R^b are each independently hydrogen, OH, $OCOR^9$, NH_2, N_3, $NHCOOR^9$, $NHCOCOR^9$, or F;

X is H, CF_3, OCF_3, halogen, C_1–C_7 alkyl, C_2–C_7 alkenyl, C_2–C_7 alkynyl or C_3–C_7 cycloalkyl, said alkyl, alkenyl, alkynyl or cycloalkyl group being optionally substituted by $COOR^8$, CN, $C(O)NR^6R^7$, PO_3R^8, SO_3R^8, ~~heterocyclic,~~ OR^8, SH, $S(O)_nR^9$, NR^6R^7, $NH(CO)NR^6R^7$, $NH(CO)OR^9$, or aryl ~~or heteroaryl,~~ said aryl ~~or heteroaryl~~ being optionally substituted by one or two groups independently selected from NR^6R^7, OR^8, $COOR^8$, SO_3R^8, $OCOR^9$, PO_3R^8, and $C(O)NR^6R^7$ ~~and heterocyclic~~;

R^1 and R^2 are each independently H, halogen, OR^9, C_1–C_7 alkyl, C_2–C_7 alkynyl, C_2–C_7 alkenyl or C_3–C_7 cycloalkyl, said alkyl, alkenyl, alkynyl and cycloalkyl group being optionally substituted by $COOR^8$, CN, $C(O)NR^6R^7$, PO_3R^8, SO_3R^8, ~~heterocyclic,~~ OR^8, SH, $S(O)_nR^9$, NR^6R^7, $NH(CO)NR^6R^7$, $NH(CO)OR^9$, $OC(O)OR^9$, or aryl ~~or heteroaryl~~, said aryl and heteroaryl being optionally substituted with one or two groups independently selected from NR^6R^7, OR^8, $COOR^8$, SO_3R^8, $OCOR^9$, PO_3R^8, and $C(O)NR^6R^7$ ~~and heterocyclic~~;

R^3 and R^4 are each independently H, halogen, OR^{10}, $S(O)_nR^{10}$, C_1–C_7 alkyl, C_2–C_7 alkenyl, C_2–C_7 alkynyl or C_3–C_7 cycloalkyl, said alkyl, alkenyl, alkynyl and cycloalkyl group being optionally substituted by $COOR^8$, CN, $C(O)NR^6R^7$, PO_3R^8, SO_3R^8, ~~heterocyclic,~~ OR^8, SH, $S(O)_nR^9$, NR^6R^7, $NH(CO)NR^6R^7$, $NH(CO)OR^9$, $OC(O)OR^9$, or aryl ~~or heteroaryl,~~ said aryl ~~and heteroaryl~~ being optionally substituted by one or two groups independently selected from NR^6R^7, OR^8, $COOR^8$, SO_3R^8, $OCOR^8$, PO_3R^8, and $C(O)NR^6R^7$ ~~and heterocyclic~~, with the proviso that not all of R^3, R^4 and Y may be the same halogen;

Y is OR^{10} or $S(O)_nR^{10}$;

R^5, R^6 and R^7 are each independently H, C_1–C_7 alkyl, C_2–C_7 alkenyl, C_2-C_7 alkynyl or C_3–C_7 cycloalkyl, said alkyl, alkenyl, alkynyl and cycloalkyl group being optionally substituted by $COOR^8$, CN, OR^8, NR^8R^9, SO_3R^8, PO_3R^8, halogen, or aryl ~~or heteroaryl~~, said aryl ~~or heteroaryl~~ being optionally substituted by one or two groups independently selected from $COOR^8$, SO_3R^8, and PO_3R^8 ~~and heterocyclic~~;

R^8 is H, C_1–C_7 saturated straight chain alkyl or cycloalkyl;

R^9 is C_1–C_7 saturated straight chain alkyl or cycloalkyl;

R^{10} is C_1–C_7 alkyl, C_2–C_7 alkenyl, C_2–C_7 alkynyl, aryl or C_3–C_7 cycloalkyl, said alkyl, alkenyl, alkynyl, aryl or cycloalkyl group being optionally substituted by $COOR^8$, CN, $C(O)NR^6R^7$, PO_3R^8, SO_3R^8, ~~heterocyclic,~~ OR^8, SH, $S(O)_nR^9$, NR^6R^7, $NH(CO)NR^6R^7$, $NH(CO)OR^9$, or aryl ~~or heteroaryl,~~ said aryl ~~or heteroaryl~~ being optionally substituted by one or two groups independently selected from NR^6R^7, OR^8, $COOR^8$, SO_3R^8, $OCOR^8$, PO_3R^8, and $C(O)NR^6R^7$ ~~or heterocyclic~~; and

Z is



in which m and p each independently represent an integer of one to six, ~~R^{15}, R^{16}, R^{17} are each independently C_1–C_7 alkyl or phenyl,~~ R^{18} is C_1–C_7 alkyl and aryl represents  in which X^1 is halogen.